Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

In 2021, GSK paid Arrowhead Pharmaceuticals $120 million up front for rights to the siRNA drug. Under GSK, GSK4532990 has reached mid-stage clinical development in both MASH and alcohol-related li ...

The Vallabh/Minikel lab at the Broad Institute has selected Argonaut Manufacturing Services, Inc., "Argonaut," as the drug ...

AbbVie and ADARx Pharmaceuticals have signed a collaboration and license option agreement to develop small interfering RNA ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes ...

Carrie Mckim; Investor Relations; Codexis Inc. Stephen Dilly; Chairman of the Board, President, Chief Executive Officer, Director; Codexis Inc. Stefan Lutz; Senior V ...

The siRNA technology has has the potential to enable sustained and precise messenger RNA silencing, regulating the expression ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

Innovative delivery techniques, including high-tech nanoparticles and electroporationdevices, may convey more gene therapies ...